TRIPLE NEGATIVE BREAST NEOPLASMS

This trial tests a new drug, UCB4594, designed to help the immune system attack cancer cells by targeting a protein called HLA-G found on many tumors. It is for people with advanced solid cancers that have not responded to standard treatments. The study aims to find the safest do…

This study tests two new treatments for people with advanced triple-negative breast cancer that has spread and has low PD-L1 levels. One group gets a new drug called sacituzumab tirumotecan alone, another gets it combined with pembrolizumab, and a third gets standard chemotherapy…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This study tests whether combining two drugs, bicalutamide and abemaciclib, can control a rare type of advanced breast cancer called androgen receptor-positive triple-negative breast cancer. About 53 women with inoperable or metastatic disease will receive the treatment. The main…

This study is for people with triple-negative breast cancer whose tumor did not completely disappear after initial chemotherapy plus immunotherapy. The goal is to see if adding two drugs—pembrolizumab and capecitabine—after surgery can help prevent the cancer from coming back. Ab…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests whether adding a targeted therapy (Sac-TMT) to standard chemotherapy and immunotherapy before surgery helps eliminate more cancer in high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer. About 2,400 participants will receive …

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…